Pancragen vs Carnosine
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Carnosine is an endogenous dipeptide (beta-alanine + histidine) found in high concentrations in muscle and brain. It is a potent anti-aging molecule with broad spectrum antioxidant, anti-glycation, anti-carbonylation, and metal chelating properties, making it one of the most protective naturally occurring dipeptides.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
- Admin Route
- SubQ, Oral
- Oral, Topical
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 1,000–2,000 mg
- Frequency
- Daily for 10–30 days
- Once to twice daily with meals
- Key Benefits
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Potent anti-glycation (prevents protein cross-linking/aging)
- Broad-spectrum antioxidant in muscle and brain
- Extends cell lifespan and protects telomeres
- Improves muscle performance and delays fatigue (pH buffering)
- Neuroprotective against Alzheimer's amyloid-beta
- Wound healing acceleration
- Anti-cataract properties (eye health)
- Improves diabetes complications via AGE prevention
- Chelates excess copper and zinc
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Very well tolerated
- Rare: mild GI discomfort at high doses
- No significant adverse effects in human studies
- Stacks With
- —
- —